[Other] Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Loocbomb Post time Yesterday 23:45 | Show all posts |Read mode

This post will be closed automatically in 2026-07-18 23:44

Reward20points

O’Brien M, Paz-Ares L, Marreaud S et al.
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
The Lancet Oncology, 2022; 23, 1274-1286

Reply

All Reply0 Show all posts

Loocbomb Lv.2

Junior Member

[Other] Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial Copy